COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as Second Line Therapy for Essential Thrombocythemia

Protocol No
PHARMAESSENTIA-P1101-ET
Principal Investigator
Laura Michaelis
Phase
III
Summary
The goal of P1101 is to reduce the risk of thrombosis and bleeding and to slow disease progression. In addition, this study is looking at the effectiveness of long-term therapy on whether the drug is safe or not.
Description
Ropeginterferon Alfa-2b (P1101) v. Anagrelide in ET Patients w/Hydroxyurea Resistance or Intolerance
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL